Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

CLL Society Requests the FDA to Allow for Continued Use of Already Approved PI3K Inhibitors in CLL/SLL Patients with No Other Approved Treatment Options

This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.

In June 2022, CLL Society penned a letter to the FDA that received signatures of support from 40 of the top CLL/SLL physicians in the country.

CLL Society thanked the FDA for keeping a watchful eye on this class of potentially drugs, while reminding them that CLL/SLL is not yet a solved disease.

There are very few therapies remaining besides PI3K inhibitors for those who have double refractory disease (when both BTKi and BCL2 medications are no longer an option). Patients who are double refractory still have the option of enrolling in clinical trials. But for many throughout the US, clinical trials are not an easily accessible option.

Read our letter here.